Overview

Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma

Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to characterize the safety/tolerability of pazopanib and lapatinib when administered in combination with enzyme-inducing anticonvulsants in patients with recurrent Grade III or IV malignant gliomas.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Lapatinib